Skip to main content

Table 2 Sojourn times and Normalized Transition Rates (NTR) in the steady phase

From: Chronic escitalopram treatment attenuated the accelerated rapid eye movement sleep transitions after selective rapid eye movement sleep deprivation: a model-based analysis using Markov chains

Steady phase (2001-7200 s)
Group WAKE NREM REM
  Sojourn time (s) L U Sojourn time (s) L U Sojourn time (s) L U
RD-SSRI 25.939 *# 22.668 29.681 49.719 44.440 55.625 43.633 #& 35.921 53.001
HC-SSRI 17.051 14.901 19.511 54.452 48.670 60.921 65.816 * 54.183 79.946
RD-VEH 23.081 * 20.442 26.061 40.459 36.157 45.273 20.999 * 18.379 23.994
HC-VEH 17.199 15.031 19.681 46.758 41.793 52.312 32.844 27.039 39.896
  WAKE → NREM NREM → WAKE    
  NTR L U NTR L U    
RD-SSRI 0.631 *# 0.528 0.755 0.836 0.696 1.005    
HC-SSRI 0.970 0.819 1.150 0.938 0.800 1.099    
RD-VEH 0.685 * 0.573 0.819 0.831 * 0.695 0.993    
  WAKE → REM REM → WAKE    
  NTR L U NTR L U    
RD-SSRI 0.940 0.562 1.573 0.820 0.535 1.255    
HC-SSRI 1.347 0.822 2.206 0.518 * 0.282 0.951    
RD-VEH 1.277 0.768 2.123 1.208 0.853 1.710    
  NREM → REM REM → NREM    
  NTR L U NTR L U    
RD-SSRI 1.274 #& 0.975 1.665 0.709 & 0.497 1.013    
HC-SSRI 0.605 * 0.453 0.806 0.486 * 0.297 0.796    
RD-VEH 2.198 * 1.739 2.779 1.796 * 1.382 2.334    
  1. Sojourn time: the estimated mean of the average time span of an event;
  2. Normalized Transition Rate (NTR): relative transition rate compared to the HC-VEH group (NTR of the HC-VEH group is 1);
  3. L and U: lower and the upper limits of the corresponding 95% confidence interval, respectively;
  4. * p < 0.05, significant effect compared to the HC-VEH group;
  5. #p < 0.05, significant effect compared to the HC-SSRI group;
  6. &p < 0.05, significant effect compared to RD-VEH group;
  7. Groups: home cage plus chronic vehicle treatment (HC-VEH); home cage plus chronic escitalopram treatment (HC-SSRI); REM sleep deprivation plus chronic vehicle treatment (RD-VEH); REM sleep deprivation plus chronic escitalopram treatment (RD-SSRI).